https://pharmrussia.org/ https://pharmrussia.org/feed https://pharmrussia.org/about https://pharmrussia.org/editorial https://pharmrussia.org/approvals https://pharmrussia.org/russia https://pharmrussia.org/record/ed5571f2dcae3bda0d91489673961f6954748ded https://pharmrussia.org/record/945c4a4f3e5a14a8e83162160ef58346cce2b0d9 https://pharmrussia.org/news/fda-odobrilo-pervuyu-v-mire-plazmidnuyu-dnk-immunoterapiyu-rrp-v-kombina-83017b https://pharmrussia.org/news/avstraliyskaya-eilean-therapeutics-zapustila-v-rossii-ki-chetvertogo-sob-4321f4 https://pharmrussia.org/news/boehringer-ingelheim-vykupit-prava-na-shest-kitayskih-onkopreparatov-za-b2b789 https://pharmrussia.org/news/v-ssha-odobrili-novoe-pokazanie-preparata-astrazeneca-pri-redkoy-bolezni-24aa50 https://pharmrussia.org/news/trigeptanoin-dodzholvi-odobren-dlya-lecheniya-vzroslyh-i-detey-s-gruppoy-c5aa7a https://pharmrussia.org/news/mhra-odobrilo-lechenie-geneticheskim-redaktirovaniem-dlya-detey-v-vozras-e5b144 https://pharmrussia.org/news/communicating-drug-interaction-and-qtc-information-in-the-u-s-prescribin-413d63 https://pharmrussia.org/news/advancing-generic-drug-development-leveraging-model-integrated-evidence-8b3403 https://pharmrussia.org/news/use-of-non-oecd-mad-non-clinical-data-in-support-of-uk-clinical-trial-au-7a6d68 https://pharmrussia.org/news/ekspert-rospotrebnadzora-potrebovala-srochno-izmenit-instruktsii-anatoks-a3049b https://pharmrussia.org/news/how-to-register-a-drug-establishment-9ded14 https://pharmrussia.org/news/guangzhou-jiugong-research-and-development-biotechnology-co-ltd-737769-1-fc6080 https://pharmrussia.org/news/jing-cheong-asia-inc-dba-new-york-tong-ren-tang-738200-10-26-2026-0be3e4 https://pharmrussia.org/news/issledovanie-vklyuchenie-vaktsinatsii-protiv-vpch-v-natskalendar-v-2027-53d819 https://pharmrussia.org/news/sud-podtverdil-pravo-patsienta-s-bas-na-nezaregistrirovannyy-preparat-b35474 https://pharmrussia.org/news/ozon-farmatsevtika-poluchila-registratsiyu-na-pervyy-sobstvennyy-bioprep-787ad8 https://pharmrussia.org/news/tatyana-golikova-postavila-zadachu-operativno-informirovat-kliniki-ob-ot-1e058c https://pharmrussia.org/news/fda-odobrilo-atezolizumab-v-sochetanii-s-himioterapiey-dlya-lecheniya-ra-5f7c11 https://pharmrussia.org/news/fda-odobrilo-pervuyu-dnk-terapiyu-papillomatoza-f6e506 https://pharmrussia.org/news/minzdrav-rossii-prinuditelno-otmenil-registratsiyu-dekarisa-i-otozval-es-cf2e74 https://pharmrussia.org/news/zarubezhnye-farmproizvoditeli-predlozhili-dorabotat-pravila-prinuditelno-2f874c https://pharmrussia.org/news/patsienty-soobschili-o-dolgom-ozhidanii-lekarstv-dazhe-posle-vyneseniya-ea7144 https://pharmrussia.org/news/olesya-filatova-kak-menyaetsya-kreativ-v-farmkommunikatsiyah-104248 https://pharmrussia.org/news/v-rossii-protestiruyut-analog-antipsihotika-novogo-klassa-ot-bms-b53183 https://pharmrussia.org/news/preparat-rosteha-biogam-odobrili-dlya-lecheniya-detey-s-narusheniyami-im-ee9571 https://pharmrussia.org/news/fda-predlozhilo-mehanizm-plug-and-play-dlya-registratsii-individualiziro-b536fd https://pharmrussia.org/news/fda-odobrilo-pervyy-v-svoem-rode-preparat-dlya-lecheniya-hronicheskogo-g-54a825 https://pharmrussia.org/news/fda-vydalo-uskorennuyu-registratsiyu-dostarlimabu-dzhemperli-dlya-lechen-96a7b8 https://pharmrussia.org/news/polozhitelnoe-zaklyuchenie-ema-chmp-po-preparatu-rasonke-daraksonrasib-p-53de2a https://pharmrussia.org/news/fda-zapuskaet-ramochnuyu-initsiativu-po-redkim-zabolevaniyam-chtoby-adap-ecb71b https://pharmrussia.org/news/strategiya-mhra-2030-po-modernizatsii-regulirovaniya-orientirovannogo-na-2d83fd https://pharmrussia.org/news/fda-odobrilo-pervoe-lechenie-defitsita-mct8-8f37e9 https://pharmrussia.org/news/mhra-odobrilo-lurbinektin-dlya-vzroslyh-s-melkokletochnym-rakom-legkogo-05498c https://pharmrussia.org/news/osnovnye-momenty-zasedaniya-chmp-14-17-sentyabrya-2026-g-5d0f76 https://pharmrussia.org/news/fda-uskorilo-odobrenie-novogo-metoda-lecheniya-raka-molochnoy-zhelezy-604c2f https://pharmrussia.org/news/fda-odobrilo-pervyy-preparat-dlya-lecheniya-bolezni-aleksandera-642e51 https://pharmrussia.org/news/fda-ischet-obschestvennyy-vklad-dlya-prodvizheniya-razrabotki-lekarstven-5e364a https://pharmrussia.org/news/kratkaya-osnova-resheniya-po-enflonsii-09ea0c https://pharmrussia.org/news/fda-odobrilo-pervyy-v-svoem-klasse-preparat-mimril-rusfertid-dlya-lechen-5faf25 https://pharmrussia.org/news/fda-odobrilo-pervyy-peroralnyy-preparat-ot-dermatomiozita-u-vzroslyh-4fd9d3 https://pharmrussia.org/news/fda-odobrilo-pervuyu-v-svoem-klasse-targetnuyu-terapiyu-metastaticheskog-e44d62 https://pharmrussia.org/news/uskorennoe-odobrenie-fda-genglikosa-pariglasgene-brecaparvovec-opnr-dlya-792721 https://pharmrussia.org/news/fda-odobrilo-pervoe-v-svoem-rode-robotizirovannoe-ustroystvo-dlya-vzyati-414ca0 https://pharmrussia.org/news/mhra-izlagaet-pozitsiyu-po-regulirovaniyu-lekarstvennyh-sredstv-na-osnov-605472 https://pharmrussia.org/news/u-tebya-est-otsenki-no-ne-sdavay-svoe-zdorove-cfaaf0 https://pharmrussia.org/news/velikobritaniya-pervoy-v-evrope-razreshila-ispolzovanie-orforgliprona-dl-8d4b25 https://pharmrussia.org/news/fda-odobrilo-novuyu-inzhenernuyu-virusnuyu-immunoterapiyu-dlya-lecheniya-944ea2 https://pharmrussia.org/news/fda-odobrilo-pervyy-preparat-dlya-lecheniya-vsego-spektra-simptomov-nark-656eaf https://pharmrussia.org/news/mhra-odobrilo-remibrutinib-dlya-lecheniya-hronicheskoy-spontannoy-krapiv-82e392 https://pharmrussia.org/news/tysyachi-patsientov-poluchat-polzu-ot-novyh-ezhednevnyh-tabletok-ot-sere-4628c8 https://pharmrussia.org/news/fda-litsenziruet-pervyy-v-mire-produkt-liofilizirovannoy-plazmy-v-ssha-f96467 https://pharmrussia.org/news/chmp-opublikoval-osnovnye-momenty-vstrechi-v-iyule-2026-goda-1fbb72 https://pharmrussia.org/news/fda-warns-about-dental-problems-with-buprenorphine-medicines-dissolved-i-79a00b https://pharmrussia.org/tag/atezolizumab https://pharmrussia.org/tag/daraxonrasib https://pharmrussia.org/tag/ema https://pharmrussia.org/tag/fda https://pharmrussia.org/tag/mhra https://pharmrussia.org/tag/ru